Proceeds to be used to develop first-in-class arginase inhibitors for cardiovascular and pulmonary indications BALTIMORE, MD, Oct., 2–(HSMN NewsFeed)–Arginetix, Inc. today announced it has closed a $10.75 million Series A financing. The company is dev…
Biopharmaceuticals, Venture Capital
Arginetix

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Arginetix Closes $10.75 Million Series A Financing”
Leave a Comment